*
Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree
54321
The information and/or skills learned will enhance my professional competence or ability.
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence
54321
Implement therapeutic strategies when treating hematologic malignancies.
*
Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice
543210
Summarize the evolving therapeutic strategies in the treatment of hematologic malignancies.
Provide an update of new molecular and immunological treatments being developed for these diseases.
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA= Not Applicable
54321NA
Richard Stone, M.D. - Treatment Approached for high-risk Acute Myeloid Leukemia in 2022
Eytan Stein, M.D. - Overcoming Resistance to Targeted therapies in Acute Myeloid Leukemia
Raajit Rampal, M.D. - Myelofibrosis: Current and Emerging Treatments
Hagop Kantarjian, M.D. - Updates on Treatment Approaches for Acute Lymphoblastic Leukemia
Wendy Stock, M.D. - Improving Outcomes in T-ALL: Challenges and New Directions
Paul Richardson, M.D. - Treatment approaches for Multiple Myeloma in 2022
Adam Cohen, M.D. - Update on BCMA-Directed Therapies for Multiple Myeloma
Guenther Koehne, M.D., Ph.D. - Wilms’ Tumor antigen 1 in Multiple Myeloma
Charles Dimitroff, Ph.D. - Signature human B-Cell surface Glycosylation Can Provide Key Insights for Treating B-Cell malignancies
Matthew Matasar, M.D. - Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL)
*
*
*
*
*